NB Postech said Monday that it has signed a technology transfer agreement with Seoul National University (SNU) for the latter’s fluorescence signal enhancement nanocomposite.
|NB Postech CEO Park Joon-won, from right, Seoul National University R＆DB Foundation Business Affairs Department head Lee Chang-gun, and Professor Nam Jwa-min pose after signing the technology transfer agreement at the university, last Thursday.|
Under the accord, the company has exclusively acquired the university’s fluorescence signal enhancement nanocomposite developed by Professor Nam Jwa-min of the university’s chemistry department.
According to the company, Professor Nam is a world-renowned expert in nanoparticle synthesis, optical nanoprobe, and nanobiotechnology.
The fluorescence signal enhancement technology secured with the contract amplifies the signal with high efficiency in a surface controlled environment. It allows users to distinguish detection signals from extraneous background signals further.
“The signing of the contract is meaningful as the company can create a synergetic technology by combining its surface control and signal amplification, which will secure our competitiveness in the ultra-high sensitive diagnostic market,” the company said.
The ultra-high sensitivity diagnostic is an essential technology required in the early diagnosis market such as acute myocardial infarction diagnosis and infectious disease test. It plays a crucial factor as it enables medial professional to give the most effective measure promptly.
The company plans launch commercialization strategy, marketing, and sales along with Handok, its top shareholder, and accelerate the entry into the global diagnostic market.
<© Korea Biomedical Review, All rights reserved.>